Chemical inhibitors of ZNF460 can impact its function through various mechanisms by targeting different cellular kinases and pathways that are involved in the regulation of this protein's activity. Alsterpaullone, a cyclin-dependent kinase inhibitor, can prevent phosphorylation events that are necessary for ZNF460's activity, thus leading to its functional inhibition. Similarly, Indirubin-3'-monoxime can inhibit GSK-3β, which may phosphorylate proteins that interact with ZNF460, altering their interaction and ZNF460's regulatory functions. SP600125, by inhibiting JNK, can prevent the activation of transcription factors that regulate ZNF460's activity or its binding to DNA. Y-27632 specifically targets ROCK kinases which can be involved in the cytoskeletal organization necessary for ZNF460's proper subcellular localization and function. By impeding the proper localization of ZNF460, Y-27632 can hamper its function within the cell.
Continuing with the theme of kinase inhibition, SB203580 can disrupt p38 MAPK signaling which can result in decreased functional activity of ZNF460, especially if ZNF460 is a transcriptional activator that responds to MAPK pathway signals. PD98059 and U0126, both MEK inhibitors, can lead to a reduction in ZNF460 activity by preventing necessary phosphorylation events that would typically be mediated by the activation of ERK. LY294002, a PI3K inhibitor, can decrease phosphorylation of downstream targets that are involved in the regulation of ZNF460's function. Rapamycin, by inhibiting mTOR, can disrupt signals that are essential for ZNF460's full functional activity. Furthermore, Thapsigargin can affect the protein's function by disrupting calcium homeostasis, which may be crucial for ZNF460's proper folding or regulatory modification. Lastly, Brefeldin A and Cyclopamine can inhibit intracellular protein transport and the Hedgehog signaling pathway, respectively, leading to mislocalization of ZNF460 or inhibition of its regulatory functions that depend on these pathways, thereby inhibiting the protein's activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $67.00 $306.00 | 2 | |
Alsterpaullone is known to inhibit cyclin-dependent kinases. ZNF460, as a zinc finger protein, may interact with phosphorylated substrates or be regulated by phosphorylation. Inhibition of cyclin-dependent kinases by alsterpaullone could prevent phosphorylation events necessary for ZNF460's activity, leading to its functional inhibition. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $77.00 $315.00 $658.00 | 1 | |
Indirubin-3'-monoxime inhibits GSK-3β, a kinase that could phosphorylate proteins interacting with ZNF460, altering their interaction and function. This chemical, by inhibiting GSK-3β, could therefore disrupt protein-protein interactions necessary for ZNF460 to exert its regulatory functions, resulting in the inhibition of ZNF460. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125 is a JNK inhibitor. JNK can modulate transcription factors that potentially regulate ZNF460's activity or its binding to DNA. By inhibiting JNK, SP600125 could prevent the activation of those transcription factors, leading to a decrease in ZNF460's functional activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 targets ROCK kinases which are involved in cytoskeletal organization, a process that may be crucial for ZNF460's subcellular localization and function. Inhibition of ROCK by Y-27632 could thus impede the proper localization of ZNF460, hampering its functional role within the cell. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. Inhibition of p38 MAPK could disrupt downstream signaling that regulates ZNF460 activity, especially if ZNF460 acts as a transcriptional activator in response to signals mediated by the MAPK pathway. This could lead to a decrease in ZNF460's functional activity in the cell. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an MEK inhibitor, which could prevent the activation of ERK, a kinase that may phosphorylate ZNF460 or its cofactors, influencing ZNF460 activity. By inhibiting MEK, PD98059 could therefore lead to a reduction of ZNF460 functional activity by preventing necessary phosphorylation events. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is another MEK inhibitor that could inhibit the activation of ERK, which in turn could be necessary for the phosphorylation of ZNF460 or associated regulatory proteins. Through this inhibition, U0126 would result in diminished ZNF460 activity due to a lack of essential phosphorylation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor, which could decrease the phosphorylation of downstream targets involved in the regulation of ZNF460's function. By inhibiting PI3K, LY294002 could lead to the inhibition of ZNF460's activity by disrupting necessary signaling events. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which is part of signaling pathways that control cell growth and may regulate ZNF460 activity. Inhibition of mTOR by rapamycin could disrupt signals that are essential for the full functional activity of ZNF460. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin inhibits the SERCA pump, affecting calcium homeostasis in the cell. Calcium signaling could be essential for the proper folding or regulatory modification of ZNF460. By disrupting calcium homeostasis, thapsigargin could lead to functional inhibition of ZNF460. |